Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urothelial Cancer 1Urinary Bladder Neoplasms 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1

Interventions

Magnetic Resonance Spectroscopy 98Specimen Handling 79pembrolizumab 75enzalutamide 63Nivolumab 59Gemcitabine 54Docetaxel 50apalutamide 42Radiosurgery 41Abiraterone Acetate 40Androgen Antagonists 39Prednisone 38Biopsy 37darolutamide 35Cisplatin 35cabozantinib 31Radiotherapy 31Carboplatin 28Pluvicto 27abiraterone 26enfortumab vedotin 24Ipilimumab 24Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 18X-Rays 18Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
vinflunine × Genitourinary × 90 days × Clear all
NCT04527991 2026-06-02

TROPiCS-04

Gilead Sciences

Phase 3 Completed
711 enrolled 25 charts
Genitourinary

Locally Advanced or Metastatic Unresectable Urothelial Cancer

NCT07419295 2026-05-29

TroFuse-031

Merck Sharp & Dohme LLC

Phase 3 Recruiting
590 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting
629 enrolled 32 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡